DrugPatentWatch Database Preview
Drugs in Development Information for Patritumab
» See Plans and Pricing
What is the development status for investigational drug Patritumab?
Patritumab is an investigational drug.
There have been 9 clinical trials for Patritumab.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2014.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Daiichi Sankyo Inc., Daiichi Sankyo, Inc., and SCRI Development Innovations, LLC.
There are eight US patents protecting this investigational drug and one hundred and ninety-six international patents.
Summary for Patritumab
| US Patents | 8 |
| International Patents | 196 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2014-03-01) |
| Vendors | 0 |
Recent Clinical Trials for Patritumab
| Title | Sponsor | Phase |
|---|---|---|
| A Study of U3-1402 in Subjects With Metastatic Breast Cancer | Daiichi Sankyo, Inc. | Phase 2 |
| A Study of U3-1402 in Subjects With Metastatic Breast Cancer | SCRI Development Innovations, LLC | Phase 2 |
| Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | Daiichi Sankyo, Inc. | Phase 1 |
Clinical Trial Summary for Patritumab
Top disease conditions for Patritumab
Top clinical trial sponsors for Patritumab
US Patents for Patritumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Patritumab | Start Trial | Multispecific constructs | AbbVie Stemcentrx LLC (North Chicago, IL) | Start Trial |
| Patritumab | Start Trial | Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein | CureVac AG (Tubingen, DE) | Start Trial |
| Patritumab | Start Trial | Binding-triggered transcriptional switches and methods of use thereof | The Regents of the University of California (Oakland, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Patritumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Patritumab | Canada | CA2900764 | 2033-02-08 | Start Trial |
| Patritumab | European Patent Office | EP2954056 | 2033-02-08 | Start Trial |
| Patritumab | Hong Kong | HK1218930 | 2033-02-08 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
